Innovation in pharmaceutics

Innovation in pharmaceuticals can sometimes be consistent with public goals in both economic and health sectors. To the extent that technological change improves health and if R D is conducted in the country, innovation promotes employment and income-increasing goals as well. Also, a healthy population is more likely to make for an economically productive workforce. 

While expenditures on pharmaceuticals have risen, there is empirical evidence that innovation in pharmaceuticals has been an important contributor to improved health of the population in many countries (Cutler 2004). Pharmaceutical innovation, such as new drugs for hypertension and high cholesterol, accounts for about one-third of the reduction in cardiovascular disease in the United States (Cremieux et ah. Chapter 12 Cutler and Kadiyala 2003). 

A common issue in these aggregated studies is howto measure innovation in pharmaceuticals. Three different types of measures have been used (1) the cumulative number of drugs approved with NMEs, (2) newer drugs as a proportion of total physician prescriptions, (3) and the average vintage of drugs. 

Discussion of the current state by major publications such as The Economist (8), the Wall Street Journal (9) and the Business Week (10) add to a growing awareness of a need for improvement. An excellent analysis of the current state of manufacturing process innovation in pharmaceutical and biotechnology industry was described in 1996 by Pisano (11). 

The Cost of Innovation in Pharmaceutical Industry New Drug R D Cost... 

Wu, T.-C., Ramachandran, V. Pharmaceutical applications of Heck chemistry. Innovations in Pharmaceutical Technology 2000, 97-101. 

Yates, I. (2006) Lab automation implementing a successful system to support drug discovery. Innovations in Pharmaceutical Technology, 20, 30 34. 

S.C. Stallings et ah. Technological Innovation in Pharmaceuticals, Pharmaceutical Discovery and Development, PharmaVentures/MIT, Cambridge, MA, 2001. 

Listro, T. Foamed hot melt extrusion for solid molecular dispersions. Innovation in Pharmaceutical Technology. 2012, 43, 60-62. 

Cheeseright, T. (2009) The identification of bioisosteres as drug development candidates. Innovations in Pharmaceutical Technology, 28, 22-26. 

Gauthier, S.F., Pouliot, Y., Saint-Sauveur, D., 2006. Immunomodulatory peptides obtained by the enzymatic hydrolysis of whey proteins. International Dairy Journal 16, 1315—1323. Ghilzai, M., June 2004. Advances in the delivery of large-size drug molecules. Innovations in Pharmaceutical Technology 103—108. 

Report, various EU-funded projects on innovation, employment, finance and growth, such as AITEG and FINNOV, and to research on innovation in pharmaceuticals with the Edinburgh-OU ESRC INNOGEN Centre. 

Soltero R, Ekwuribe N. The oral delivery ofprotein and peptide drugs. Innovations in pharmaceutical technology (Online Journal). 106-110. 

---